Monthly Archive:: February 2019

Bayer Completes Rolling Submission of NDA for Investigational Drug Darolutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

darolutamide Treatment for Prostate Cancer Bayer Completes Rolling Submission of NDA for Investigational Drug Darolutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Print this page WHIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ — Bayer today announced the completion of …